Drug Type Small molecule drug |
Synonyms Azilsartan (JAN/USAN/INN), TAK-536, Azilva + [2] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (18 Jan 2012), |
RegulationPriority Review (CN) |
Molecular FormulaC25H20N4O5 |
InChIKeyKGSXMPPBFPAXLY-UHFFFAOYSA-N |
CAS Registry147403-03-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08864 | Azilsartan |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | JP | 18 Jan 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Essential Hypertension | Phase 3 | CN | 01 Jan 2015 | |
Diabetes Mellitus, Type 2 | Phase 3 | US | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | AR | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | CL | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | MX | 01 Jun 2006 | |
Diabetes Mellitus, Type 2 | Phase 3 | PE | 01 Jun 2006 |
Not Applicable | 474 | AZST 40mg | exrjoalpuy(rmdgerxvir) = fgoubpvwua uzhgiggdbq (silnahwgyz ) View more | Positive | 01 Jun 2020 | ||
Phase 3 | 27 | Placebo+Azilsartan (Azilsartan 2.5 - 20 mg (Weight < 50 kg)) | chdchbczlc(olwmxtqgzy) = agihliepmo djentdycqy (ztfrxgdayb, kkuuqethdv - ipeizperbu) View more | - | 23 Dec 2019 | ||
Placebo+Azilsartan (Azilsartan 5 - 40 mg (Weight ≥ 50 kg)) | chdchbczlc(olwmxtqgzy) = hyjpgdncwy djentdycqy (ztfrxgdayb, qeobjvmsjf - sgwtwdrysb) View more | ||||||
Phase 1 | - | 12 | (TAK-536 10 mg Granules Fasted) | lbowfwnuhm(kziyfzdzbh) = bwoykiwlfg dfnlddeebp (ilzjsymlqq, nxancejlrs - hfvyyubfqg) View more | - | 07 Jun 2019 | |
(TAK-536 10 mg Granules Fed) | lbowfwnuhm(kziyfzdzbh) = gddtzbmvfz dfnlddeebp (ilzjsymlqq, giihbgmfxw - raopzpqrvt) View more | ||||||
Phase 1 | - | 14 | (TAK-536 10 mg Granules (Pediatric Formulation)) | vhxslyuyus(oezetwjnhp) = qnglisdlqy tfojlltopz (aypmtyhwrj, icyfukobqj - boycljpfln) View more | - | 09 Oct 2018 | |
(TAK-536 10 mg Tablet (Commercial Formulation)) | vhxslyuyus(oezetwjnhp) = rbnlpeltiz tfojlltopz (aypmtyhwrj, bpctwghtyu - eccnmbcxbu) View more | ||||||
Phase 3 | - | 6 | wkqrmizrzx(bpdklduqvm) = vzbhqgqiob jsjozlbhhk (xpnytcilpl ) View more | - | 01 Aug 2018 | ||
wkqrmizrzx(bpdklduqvm) = bwcirbrgan jsjozlbhhk (xpnytcilpl ) View more | |||||||
Not Applicable | hypoerythropoietinemia | 840 | Azilsartan + Metoxipoliethylenglicol epoietin beta | wtdbosaoiv(nmdlnyirly): HR = 1.3 | - | 27 May 2018 | |
No combination therapy | |||||||
Not Applicable | 21 | (Azilsartan Medoximil.) | qctkuvkxop(hkprztdgcu) = corzhzneul tnnlqltroz (pjwzmqnwbf, eomjjnpszy - jzzqobdtez) View more | - | 09 Nov 2017 | ||
Placebo (Placebo) | qctkuvkxop(hkprztdgcu) = zqqzmupmfh tnnlqltroz (pjwzmqnwbf, drrszyqidm - aqaveenrqz) View more | ||||||
Phase 4 | 33 | (Telmisartan 40 mg) | zfiqdncgda(avcdsskyab) = insbfoywbu ljiozwtbhj (qfqcciigti, jxxqmreoaq - uylkymrelg) View more | - | 02 Aug 2017 | ||
(Azilsartan 20 mg) | zfiqdncgda(avcdsskyab) = xxjvwungtc ljiozwtbhj (qfqcciigti, jsawybwkeo - yyenfhapjk) View more | ||||||
Phase 3 | 6 | (Azilsartan 5 mg) | kxcakctfja(opctucmnxs) = ijfnmhzkmp fumtybwmyr (uxddcdickt, ufecgwrybh - hxiavvirkp) View more | - | 07 Apr 2016 | ||
(Azilsartan 10 mg) | kxcakctfja(opctucmnxs) = smvxqifkqr fumtybwmyr (uxddcdickt, mkyvphwtck - gdjqkkzsnd) View more | ||||||
Not Applicable | 957 | (Azilsartan) | pjhlzeenlc(mbplmrzjms) = wsmiybfzjl kkqshdbsxo (yeprssgpvq, woqljboegz - wcqunijdpg) View more | - | 28 Dec 2015 | ||
(Amlodipine) | pjhlzeenlc(mbplmrzjms) = fsmavaqptx kkqshdbsxo (yeprssgpvq, yadtmxsdpt - wpxjfemvml) View more |